Company intelligence / Profile preview
Ancora Global
Newark, California, United Statesancoraglobal.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ancora Biotech develops multi-specific antibodies targeting major unmet needs in oncology, metabolic/inflammatory disease, and infectious disease. Its lead programs are at preclinical to early clinical stages. Notably, its spin-off TeneoTwo’s asset was acquired by AstraZeneca after promising early results in B-cell cancer therapy. The company leverages deep expertise from former leaders at Teneobio and has raised significant venture capital funding ($60M Series A).
- Therapeutic areas
- Metabolic DisordersPsychiatryInfectious DiseasesOncologyImmunology
- Modalities
- Monoclonal antibodyT cell engagerEnzyme inhibitorSmall molecule drug
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Notable past partnerships via founders’ previous companies with Amgen, Celgene Corporation, Genmab A/S, Janssen Pharmaceuticals Inc., Merck KGaAAstraZeneca acquired one spin-off asset from Ancora’s portfolioInvestors include SR One and Lightspeed Venture Partners
Beyond the preview
Go deeper on Ancora Global.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ancora Global.